The Role of Amylin in Bone Metabolism

NARecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 12, 2024

Primary Completion Date

August 1, 2024

Study Completion Date

August 1, 2024

Conditions
Bone Diseases, MetabolicType 1 Diabetes
Interventions
OTHER

Pramlintide

At time 0 min, continuous infusion of a stable amylin analogue (pramlintide) will be initiated at a rate of 3.0 pmol/kg/min. The infusion will be terminated after 180 minutes.

OTHER

Placebo (saline) infusion

At time 0 min, continuous infusion of isotonic saline will be initiated at a rate of 150 ml/h. The infusion will be terminated after 180 minutes.

Trial Locations (1)

2900

RECRUITING

Center for Clinical Metabolic Research, Gentofte Hospital, Hellerup

All Listed Sponsors
lead

Filip Krag Knop

OTHER